

**Supplementary Figure 1:** Frequency of the different treatment options administered and mean of treatment duration/months.



**Supplementary Figure 2:** DLQI as ordered by mean scores obtained for each item. DLQI: Dermatology Life Quality Index.

**Supplementary Table 1: Demographic characteristics of the patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Demographic characteristics** | **Total (*n* = 1662)** | **Males (*n* = 823)** | **Females (*n* = 839)** |
| Age (years), mean (SD) | 38.8 (11.5) | 37.7 (11.2) | 39.9 (11.7)\* |
| Civil status, *n* (%) |  |  |  |
|  Married or have a spouse | 1273 (76.6) | 607 (73.8) | 666 (79.4)\* |
|  Unmarried or no spouse | 389 (23.4) | 216 (26.2)\* | 173 (20.6) |
| Educational level, *n* (%) |  |  |  |
|  ≤High school | 802 (48.3) | 343 (41.7) | 459 (54.7)\* |
|  >High school | 860 (51.7) | 480 (58.3)\* | 380 (45.3) |
| Residence, *n* (%) |  |  |  |
|  City | 1282 (77.1) | 625 (75.9) | 657 (78.3) |
|  Village | 380 (22.9) | 198 (24.1) | 182 (21.6) |
| Work and study status, *n* (%) |  |  |  |
|  Currently working or studying | 1218 (73.3) | 688 (83.6)\* | 530 (63.2) |
|  Have no work or retired | 444 (26.7) | 135 (16.4) | 309 (36.8)\* |
| Monthly income (RMB), *n* (%) |  |  |  |
|  ≤3k | 653 (39.3) | 214 (26.0) | 439 (52.3)\* |
|  3k–10k | 902 (54.3) | 537 (65.2)\* | 365 (43.5) |
|  >10k | 107 (6.4) | 72 (8.7)\* | 35 (4.2) |

\*Significance at <0.05.

**Supplementary Table 2: Clinical characteristics of the patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical characteristics** | **Total (*n* = 1662)** | **Male (*n* = 823)** | **Female (*n* = 839)** |
| Age of onset (years), mean (SD) | 24.3 (12.8) | 24.0 (11.2) | 24.6 (14.2) |
| Disease duration (years), mean (SD) | 14.6 (10.9) | 13.7 (10.1) | 15.4 (11.6)\* |
| Affected body surface area, *n* (%) |  |  |  |
|  BSA <1% | 828 (49.8) | 415 (50.4) | 413 (49.2) |
|  BSA 1–10% | 607 (36.5) | 319 (38.8) | 288 (34.4) |
|  BSA >10% | 227 (13.7) | 89 (10.8) | 138 (16.4)\* |
| Involve sites, *n* (%) |  |  |  |
|  Exposed | 921 (55.4) | 457 (55.5) | 464 (55.3) |
|  Non-exposed | 741 (44.6) | 366 (44.5) | 375 (44.7) |
| Disease type, *n* (%) |  |  |  |
|  Acrofacial | 526 (31.6) | 295 (35.8)\* | 231 (27.5) |
|  Vulgaris | 490 (29.5) | 234 (28.4) | 256 (30.5) |
|  Generalized | 194 (11.7) | 84 (10.2) | 110 (13.1) |
|  Localized | 375 (22.6) | 180 (21.9) | 195 (23.2) |
|  Segmental  | 77 (4.6) | 30 (3.6) | 47 (5.6) |
| Disease stage, *n* (%) |  |  |  |
|  Stable | 679 (40.9) | 345 (41.9) | 334 (39.8) |
|  Progressive | 894 (53.8) | 433 (52.6) | 461 (54.9) |
|  Regressive | 89 (5.4) | 45 (5.5) | 44 (5.2) |
| Onset season, *n* (%) |  |  |  |
|  Winter (December–February) | 99 (6.0) | 52 (6.3) | 47 (5.6) |
|  Summer (June–August) | 708 (42.6) | 371 (45.1)\* | 337 (40.2) |
|  Spring (March–May) | 664 (40.0) | 296 (36.0) | 368 (43.9)\* |
|  Autumn (September–November) | 191 (11.5) | 104 (12.6) | 87 (10.4) |
| Family history, *n* (%) |  |  |  |
|  Yes | 217 (13.1) | 102 (12.4) | 115 (13.7) |
|  No | 1445 (86.9) | 721 (87.6) | 724 (86.3) |
| Use of systemic medication, *n* (%) | 907 (54.6) | 412 (50.1) | 495 (59.0)\* |
| Use of topical medication, *n* (%) | 1262 (75.9) | 599 (72.7) | 663 (79.0)\* |
| Use of phototherapy and surgery, *n* (%) | 859 (51.7) | 411 (49.9) | 449 (53.5) |

\*Comparisons of column proportions significant at <0.05.